Prescription drug · ANDA
Liraglutide NDC 70377-094
Liraglutide 6 mg/mL · Injection · Subcutaneous · Biocon Pharma Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70377-094-52 | 70377009452 | 2 SYRINGE, PLASTIC in 1 CARTON (70377-094-52) / 3 mL in 1 SYRINGE, PLASTICMarketed from Apr 25, 2026 | |
| 70377-094-53 | 70377009453 | 3 SYRINGE, PLASTIC in 1 CARTON (70377-094-53) / 3 mL in 1 SYRINGE, PLASTICMarketed from Apr 25, 2026 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Liraglutide
- Generic name (nonproprietary)
- liraglutide
- Active ingredients
- Liraglutide — 6 mg/mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Labeler
- Biocon Pharma Inc.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 215245
- Marketing start
- Listing expires
- Other FDA classes
- Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)
- Identifiers
- Product ID 70377-094_be87d32a-f1c2-bdd7-6bf8-30dff2d26cc4SPL ID be87d32a-f1c2-bdd7-6bf8-30dff2d26cc4SPL set ID cb032379-043b-443c-d552-b5d25f27f3c4RxCUI 897122UNII 839I73S42AUPC 0370377094538, 0370377094521
- Pharmacologic class
- GLP-1 Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N470377009452followed by a unit qualifier and the quantityPackage 70377-0094-52. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use : Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in …
Excerpt only. Read the full label for complete information.